Ind-Swift-LTD-Best Pharmaceutical Company,Pharmaceutical Market Products in North India,Chandigarh


Celebrating Silver Jubilee	ROCHE DIAGNOSTICS partners with ISL to expand TROP T Rapid assay in India	Font Size
News Flash Ranked 97th largest Pharma company in the global market by Plimsoll Global Analysis. MBA Program From Punjabi University Patiala for Ind Swift Employees. Swift Technical campus becomes first college in INDIA to have UG courses affiliated to Foreign University along with AICTE approval Global Ranking Of Ind-Swift Ltd. Swift Group of Colleges introduces new courses in Management & Humanities. Indswift to set up deemed university in Punjab Indswift to start college in Birmingham (UK) Indswift Labs get USFDA nod for Temozolomide & Telmisartan Ind-Swiftlabs to increase its capacity by 40% over next two years. Ind-Swift net profit up by 83.10%, exports up by 37.87%. Ranked 35th among Top Pharmaceuticals companies of India. Ranked among top 500 FORTUNE companies of India Indswift labs to be first Indian company to get PMDA approval from Japan. Announcements	Troponin-T is used to measure damage to the heart muscle and to differentiate between non- cardiac chest pains and heart attacks. Roche Diagnostics India Pvt. Ltd. enters into an agreement with Ind-Swift Limited; a Chandigarh based pharmaceutical company to promote its test for detecting heart attack, TROP T rapid assay, in India. Roche Diagnostics India Pvt. Ltd. is part of Roche Group, a worldwide leader in the field of Medical Diagnostics and Pharmaceuticals. Roche Diagnostids' TROP T rapid assay is a point of care test which can detect whether a patient is having a heart attack through a simple whole blood test. Troponin-T is used to measure damage to the heart muscle and to differentiate between non-cardiac chest pains and heart attacks. The TROP T rapid assay gives a reliable qualitative result within 15 minutes. Ind-Swift Ltd. has a Cardio Specific Field Force, CARDIASWIFT which has been marketing cardio & anti-diabetic products for the last 8-10 years. Over the years, CARDIASWIFT has established a sound presence in the minds of cardiac and diabetic specialists and consulting physicians. Ind-Swift Limited will promote TROP T to cardiologists / diabectologists / consulting physicians/general practitioners all over the country with its 225 Strong Field Force. This collaboration with Roche Diagnostics India Pvt. Ltd. will give ISL a big chance to develop a strong presence in the cardiac field with some of the most established and renowned specialists and hospitals", said an elated Dr. Gopal Munjal, M.D & C.E.0, Ind-Swift Group. Speaking on the occasion, Dr. Bhuwnesh Agrawal, Chairman and Managing Director, Roche Diagnostics India and South Asia said, "With a strong commercial partner like Ind-Swift Limited we are confident to penetrate in our target markets and reach out to doctors and patients throughout India and therewith reduce the burden of cardiovascular mortality in our country". Related Links: http://pharmabiz.com/NewsDetails.aspx?aid=67006&sid=2 http://blogs.wsj.com/dealjournalindia/2012/01/13/ind-swift-roche-diagnostics-in-pact-for-selling-heart-attack-detection-kit/?mod=google_news_blog http://www.reuters.com/article/2012/01/13/india-indswift-idUSL3E8CD19H20120113 http://m.economictimes.com/PDAET/articleshow/11473575.cms http://www.caclubindia.com/reader/ind-swift-to-sell-roche-s-heart-attack-detection-kits-44982.asp#.TxAP-qXrrpA http://www.tradesignalonline.com/charts/news.aspx?id=902311&filter=&catid=0